Show simple item record

dc.contributor.authorCaloro, Matteo
dc.contributor.authorCalabrò, Giuseppa
dc.contributor.authorde Pisa, Eleonora
dc.contributor.authorRosini, Enrico
dc.contributor.authorKotzalidis, Georgios D
dc.contributor.authorLonati, Davide
dc.contributor.authorLocatelli, Carlo Alessandro
dc.contributor.authorPapa, Pietro
dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorGirardi, Paolo
dc.date.accessioned2018-07-05T16:03:38Z
dc.date.available2018-07-05T16:03:38Z
dc.date.issued2018-05-01
dc.identifier.citationCaloro , M , Calabrò , G , de Pisa , E , Rosini , E , Kotzalidis , G D , Lonati , D , Locatelli , C A , Papa , P , Schifano , F & Girardi , P 2018 , ' Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder ' , Journal of Addiction Medicine , vol. 12 , no. 3 , pp. 247-251 . https://doi.org/10.1097/ADM.0000000000000390
dc.identifier.issn1932-0620
dc.identifier.otherPURE: 13433264
dc.identifier.otherPURE UUID: 8327b933-8372-4ab4-8f83-16b33f975705
dc.identifier.otherPubMed: 29401155
dc.identifier.otherScopus: 85048164113
dc.identifier.urihttp://hdl.handle.net/2299/20270
dc.descriptionThis document is an Accepted Manuscript reprinted from Journal of Addiction Medicine, Vol. 12 (3): 247-251, May 2018, with permission of Kluwer Law International. Under embargo until 1 May 2019. The Version of Record is available online at DOI: https://doi.org/10.1097/ADM.0000000000000390
dc.description.abstract: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. CASE REPORT: We describe a case of a 32-year-old man who started at 18 years with cannabinoids and ketamine, and is currently using N-methyl-D-aspartate (NMDA) antagonists. At age 23, he developed social withdrawal after being assaulted by a stranger, but did not consult psychiatrists until age 26; during this period, he was using internet-purchased methoxetamine and ketamine, and was persecutory, irritable, suspicious, and insomniac and discontinued all received medical prescriptions. He added dextromethorphan to his list of used substances. At age 31, while using phencyclidine, and, for the first time, methoxphenidine, he developed a religious delusion, involving God calling him to reach Him, and the near-death experiences ensured by NMDA antagonists backed his purpose. He received Diagnostic and Statistical Manual of Mental Disorders, 5th Edition diagnosis of multisubstance-induced psychotic disorder and was hospitalized 8 times, 6 of which after visiting the emergency room due to the development of extreme anguish, verbal and physical aggression, and paranoia. He reportedly used methoxphenidine, methoxyphencyclidine, ethylnorketamine, norketamine, and deschlorketamine, to achieve near-death experiences, and eventually to reach God in heavens. CONCLUSIONS: This case points to the need for better control of drugs sold on the internet. It also illustrates that people using NMDA antagonists may present clinical pictures indistinguishable from those of major psychoses and are likely to be misdiagnosed.en
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofJournal of Addiction Medicine
dc.subjectinternet drug market
dc.subjectmethoxetamine
dc.subjectmethoxyphencyclidine
dc.subjectmethoxyphenidine
dc.subjectmultisubstance-induced
dc.subjectN-methyl-d-Aspartate antagonists
dc.subjectpsychosis
dc.subjectPsychiatry and Mental health
dc.subjectPharmacology (medical)
dc.titleCombined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorderen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2019-05-01
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85048164113&partnerID=8YFLogxK
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1097/ADM.0000000000000390
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record